Biotechnology Assets (BST) | Stock Overview & Key Data
Biotechnology Assets Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €13.98 on June 23, 2014
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Financial Highlights
Annual Income Flow
2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.30M Small-cap | 8.33% | 13.04% | 30.00% | -27.78% | 30.00% | -16.13% | -21.21% | -70.79% | -91.88% | -88.50% | -88.50% | |
|
Pharma Mar S.A
PHM
|
1.68B Large-cap | -2.77% | 9.23% | 17.43% | 27.39% | 23.89% | 30.10% | 151.19% | -0.37% | 186.82% | 180.20% | 30.59% |
|
Atrys Health S.A
ATRY
|
222.81M Mid-cap | -3.65% | 7.41% | -3.65% | -14.20% | -0.68% | 1.75% | -42.91% | -69.15% | 81.25% | 81.25% | 81.25% |
| 144.69M Small-cap | 11.05% | 29.80% | 115.38% | 206.25% | 134.73% | 512.50% | 497.56% | 595.04% | 595.04% | 595.04% | 595.04% | |
| 220.00M Mid-cap | -3.13% | 0.72% | -12.81% | -12.81% | -13.35% | 2.95% | 31.60% | -21.41% | -5.42% | -21.41% | -21.41% | |
|
Grifols, S.A
GRF
|
6.09B Large-cap | -7.25% | 1.24% | -18.49% | -20.87% | -20.02% | 5.17% | -3.97% | -60.31% | -52.89% | 33.98% | 244.23% |
Ownership & Short Interest
Calculate Your Biotechnology Assets Investment Returns
Long-Term Investment Performance Analysis
Biotechnology Assets stock price in Apr 2015 was €7.59, A €1,000.00 lump sum investment in Biotechnology Assets made 11 years ago would be worth approximately €34.26 today, representing a negative return of -96.57%. This translates to an annualized return (CAGR) of -26.31%.
11 Years Investment Scenario (Apr 2015 - Apr 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is BST's 52-week high and low?
- In the last 52 weeks, Biotechnology Assets reached a high of €0.49 (on July 1, 2025) and a low of €0.18 (on February 20, 2026).
- What is the market cap and P/E ratio for BST?
- Curious about Biotechnology Assets's size and valuation? Its market capitalization stands at 19.30M. When it comes to valuation, the P/E ratio (trailing twelve months) is 10.77, and the forward P/E (looking ahead) is N/A.
- Does BST pay dividends? If so, what's the yield?
- As for dividends, Biotechnology Assets isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Biotechnology Assets's main competitors or similar companies to consider before investing?
When looking at Biotechnology Assets, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Pharma Mar S.A
PHM1.68B Healthcare Biotechnology 30.10% 151.19% Atrys Health S.A
ATRY222.81M Healthcare Biotechnology 1.75% -42.91% Vytrus Biotech S.A
VYT144.69M Healthcare Biotechnology 512.50% 497.56% Oryzon Genomics S.A
ORY220.00M Healthcare Biotechnology 2.95% 31.60% Grifols, S.A
GRF6.09B Healthcare Drug Manufacturers - General 5.17% -3.97% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Biotechnology Assets S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Biotechnology Assets's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -30.40%, the Debt to Equity ratio from the most recent quarter is 33.82, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for BST?
- Looking at Biotechnology Assets's growth, its revenue over the trailing twelve months (TTM) was €3M. Compared to the same quarter last year (YoY), quarterly revenue grew by 8.00%, and quarterly earnings saw a YoY growth of N/A.
- How much of BST stock is held by insiders and institutions?
- Wondering who owns Biotechnology Assets stock? Company insiders (like executives and directors) hold about 45.27% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.10%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.